TKT
Executive Summary
Former PPD Development Regulatory Affairs Manager Helen Critchley, PhD, joins TKT as VP-international regulatory affairs, a newly created position. At PPD, she worked with TKT on the European approval of Fabry's disease therapy Replagal (1see related story, p. 20)
You may also be interested in...
Genzyme/TKT Fabry Agents Receive Co-Exclusive Orphan Drug Status In EU
Genzyme's Fabrazyme and Transkaryotic Therapies' Replagal will split the 5,000-patient Fabry's disease market in Europe following the awarding of co-exclusive orphan status by the European Commission.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials